Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risks in aspirin as CV prevention

This article was originally published in The Tan Sheet

Executive Summary

Patients and physicians should consider factors including age, gender, diabetes, blood pressure, cholesterol levels, smoking and risk of gastrointestinal bleeding before deciding to use aspirin to prevent heart attacks or strokes, an Agency for Healthcare Research and Quality panel recommends. In a March 17 Annals of Internal Medicine study, the U.S. Preventive Services Task Force found the more risk factors people have, the more likely they are to benefit from aspirin. The panel reviewed evidence from the National Institutes of Health's Women's Health Study published since its previous review of the topic in 2002. The task force recommends when the benefits outweigh the potential for GI bleeding, men between the ages of 45 and 79 should use aspirin to reduce their risk for heart attacks and women between the ages of 55 and 79 should use aspirin to reduce their risk for ischemic stroke

You may also be interested in...

Bleeding Risks Offset Aspirin’s CVD Prevention In Healthy People – Study

The routine use of aspirin to help prevent occlusive vascular events in healthy people is outweighed by an increased risk of major bleeding, suggests a meta-analysis by U.K. researchers

AAM Welcomes Proposal To Update Medicare Part D

After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts